Member Info for Kevinl1977

GMCC
Thanks for your posts.

To do this day I was away skiing, and was hoping to receive the amazing topline results of the Interferon P3 trial Synairgen ran to treat Covid 19.
Unfortunately, the news was disastrous as it failed to meet primary and secondary endpoints resulting in massive losses for investors.
Thankfully, Avacta came to the rescue for me and have enabled me to recover most of the losses I suffered.
One year on, as I’m skiing in the same place at the same time I’ve got everything crossed that Science day will bring us all some good fortune and increase the SP even more. Not forgetting, of course, the many cancer sufferers that may get life saving treatment, too.
GLA

Up to 174, down to 168/9 by the end of the day.
Just saying, predictability from the MMs.
Do is a favour….

It’s like a caged lion, MMs definitely struggling to hold this back.

Depends if you’re an optimist or a pessimist.
I’m the former :)

And of course if there’s any negative slant whatsoever, you’ll be all over it like a little school child won’t you Viking.
Because, you’re not invested but still spend your time on this board.
What a moby….

Then leave WYN.
Why are you still invested?
Obviously you aren’t invested.
Spending time on boards you aren’t invested in? Bit strange?

Touk
How did AS respond to your analytical discussion last night? Did he accept your advice? What did you tell him the next steps were?
Except you didn’t as you’re a nobody.
HE is the expert, not you. Listen to the experts!!
What a moby…..

Riesgo
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics announces that AVA6000 continues to show a very favourable safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation phase 1 clinical trial. Additionally, analysis of tumour biopsies obtained from six patients across several cohorts indicates that doxorubicin is being released within the tumour tissue confirming the tumour targeting potential of the pre|CISIONTM technology.



AVA6000 continues to be well tolerated by patients in cohort 4 with a marked reduction in the incidence and severity of the typical toxicities associated with the standard doxorubicin chemotherapy administration. Typical toxicities include alopecia, myelosuppression, nausea, vomiting, mucositis and cardiotoxicity. Importantly, even at the highest dosing levels in cohort 4, equivalent to more than double the normal dose of doxorubicin, the typical drug-related cardiotoxicity of doxorubicin was not observed.



A number of tumour biopsies obtained from patients in different cohorts have also been analysed in order to confirm the release of the active chemotherapy, doxorubicin, in the tumour tissue. This analysis shows that AVA6000 targets the release of doxorubicin to the tumour tissue at therapeutic levels which are much higher than the levels being detected in the bloodstream at the same timepoint.

Viking
I see they’ve had enough of you on the SYM board.
A little tip, so have we.

Game playing, brucies bonus?
Few delayed trades??

MMs playing games here and holding the price down. Delayed trades of that amount I’m amazed we were so in the red today.
Blue tomorrow.

Terry
How many shares do you have?
I can answer that, if you want?

Pretty sure they are sells at 159.50.

https://www.asktraders.com/analysis/avacta-shares-have-risen-43-ytd-so-why-are-they-pulling-back/
Slightly incorrect in some instances of this article, but the word is getting out.

MB
Do you realise that if that was the case someone would be looking at jail!
Drrr

DITRA
Agreed

In the recent interview he gave I made a few notes:
‘Data is unequivocal, it is being released in the tumour at double the normal level.
Delighted it is being released at significant levels analysing biopsies across several cohorts in all biopsies. Safety profile very favourable and positive but need to find MTD.
Next step higher dose concluded by this half year. Next part is dose expansion focus 1/2 cancer types 20 patients for soft tissue sarcoma begins asap later this year. In UK and 2 places being lined up in the US.
Results very promising very encouraging therapeutic level and safety too. ‘
Not my words, but the man in the know!

IMO

The resident shorter is in town.